company background image
600993 logo

Mayinglong Pharmaceutical Group SHSE:600993 Stock Report

Last Price

CN¥26.43

Market Cap

CN¥11.4b

7D

-5.5%

1Y

2.7%

Updated

27 Jul, 2024

Data

Company Financials +

Mayinglong Pharmaceutical Group Co., Ltd.

SHSE:600993 Stock Report

Market Cap: CN¥11.4b

600993 Stock Overview

Mayinglong Pharmaceutical Group Co., LTD.

600993 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends4/6

Mayinglong Pharmaceutical Group Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mayinglong Pharmaceutical Group
Historical stock prices
Current Share PriceCN¥26.43
52 Week HighCN¥31.18
52 Week LowCN¥20.20
Beta0.57
11 Month Change-0.90%
3 Month Change-3.61%
1 Year Change2.72%
33 Year Change4.71%
5 Year Change54.92%
Change since IPO1,059.24%

Recent News & Updates

Mayinglong Pharmaceutical Group's (SHSE:600993) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 24
Mayinglong Pharmaceutical Group's (SHSE:600993) Shareholders Will Receive A Bigger Dividend Than Last Year

Recent updates

Mayinglong Pharmaceutical Group's (SHSE:600993) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 24
Mayinglong Pharmaceutical Group's (SHSE:600993) Shareholders Will Receive A Bigger Dividend Than Last Year

Mayinglong Pharmaceutical Group (SHSE:600993) Has A Rock Solid Balance Sheet

Jun 19
Mayinglong Pharmaceutical Group (SHSE:600993) Has A Rock Solid Balance Sheet

Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 07
Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Investors Don't See Light At End Of Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Tunnel

Mar 22
Investors Don't See Light At End Of Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Tunnel

Shareholder Returns

600993CN PharmaceuticalsCN Market
7D-5.5%-4.0%-2.8%
1Y2.7%-18.8%-21.0%

Return vs Industry: 600993 exceeded the CN Pharmaceuticals industry which returned -18.8% over the past year.

Return vs Market: 600993 exceeded the CN Market which returned -21% over the past year.

Price Volatility

Is 600993's price volatile compared to industry and market?
600993 volatility
600993 Average Weekly Movement4.6%
Pharmaceuticals Industry Average Movement5.1%
Market Average Movement5.8%
10% most volatile stocks in CN Market9.0%
10% least volatile stocks in CN Market3.9%

Stable Share Price: 600993 has not had significant price volatility in the past 3 months.

Volatility Over Time: 600993's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
15822,882Youzhang Xiawww.mayinglong.cn

Mayinglong Pharmaceutical Group Co., LTD. engages in the manufacture, wholesale, and retail of pharmaceutical products primarily in China. The company products pipeline primarily consists of functional cosmetics, functional care products, functional food, and Chinese herbal medicines, as well as hemorrhoid, gynecological, cough, and skin products; and medical instruments.

Mayinglong Pharmaceutical Group Co., Ltd. Fundamentals Summary

How do Mayinglong Pharmaceutical Group's earnings and revenue compare to its market cap?
600993 fundamental statistics
Market capCN¥11.39b
Earnings (TTM)CN¥453.31m
Revenue (TTM)CN¥3.26b

25.1x

P/E Ratio

3.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
600993 income statement (TTM)
RevenueCN¥3.26b
Cost of RevenueCN¥1.84b
Gross ProfitCN¥1.42b
Other ExpensesCN¥965.65m
EarningsCN¥453.31m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 24, 2024

Earnings per share (EPS)1.05
Gross Margin43.54%
Net Profit Margin13.91%
Debt/Equity Ratio4.5%

How did 600993 perform over the long term?

See historical performance and comparison

Dividends

1.5%

Current Dividend Yield

38%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.